BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 16323716)

  • 1. Systemic radionuclide therapy in pain palliation.
    Liepe K; Runge R; Kotzerke J
    Am J Hosp Palliat Care; 2005; 22(6):457-64. PubMed ID: 16323716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases.
    Liepe K; Kotzerke J
    Nucl Med Commun; 2007 Aug; 28(8):623-30. PubMed ID: 17625384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The benefit of bone-seeking radiopharmaceuticals in the treatment of metastatic bone pain.
    Liepe K; Runge R; Kotzerke J
    J Cancer Res Clin Oncol; 2005 Jan; 131(1):60-6. PubMed ID: 15449184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metastatic bone pain palliation with 89-Sr and 186-Re-HEDP in breast cancer patients.
    Sciuto R; Festa A; Pasqualoni R; Semprebene A; Rea S; Bergomi S; Maini CL
    Breast Cancer Res Treat; 2001 Mar; 66(2):101-9. PubMed ID: 11437096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicentre observational study of radionuclide therapy in patients with painful bone metastases of prostate cancer.
    Dafermou A; Colamussi P; Giganti M; Cittanti C; Bestagno M; Piffanelli A
    Eur J Nucl Med; 2001 Jul; 28(7):788-98. PubMed ID: 11504074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strontium 89 therapy for the palliation of pain due to osseous metastases.
    Robinson RG; Preston DF; Schiefelbein M; Baxter KG
    JAMA; 1995 Aug; 274(5):420-4. PubMed ID: 7542352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rhenium-188-HEDP in the palliative treatment of bone metastases.
    Liepe K; Hliscs R; Kropp J; Grüning T; Runge R; Koch R; Knapp FF; Franke WG
    Cancer Biother Radiopharm; 2000 Jun; 15(3):261-5. PubMed ID: 10941533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [186Re]HEDP in the palliation of painful bone metastases from cancers other than prostate and breast.
    Minutoli F; Herberg A; Spadaro P; Restifo Pecorella G; Baldari S; Aricò D; Altavilla G; Baldari S
    Q J Nucl Med Mol Imaging; 2006 Dec; 50(4):355-62. PubMed ID: 17043634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 186Re-HEDP for metastatic bone pain in breast cancer patients.
    Lam MG; de Klerk JM; van Rijk PP
    Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S162-70. PubMed ID: 15118846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dosimetry of 188Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases.
    Liepe K; Hliscs R; Kropp J; Runge R; Knapp FF; Franke WG
    J Nucl Med; 2003 Jun; 44(6):953-60. PubMed ID: 12791825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose escalation study with rhenium-188 hydroxyethylidene diphosphonate in prostate cancer patients with osseous metastases.
    Palmedo H; Guhlke S; Bender H; Sartor J; Schoeneich G; Risse J; Grünwald F; Knapp FF; Biersack HJ
    Eur J Nucl Med; 2000 Feb; 27(2):123-30. PubMed ID: 10755716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparison of rhenium-188, rhenium-186-HEDP and strontium-89 in palliation of painful bone metastases].
    Liepe K; Franke WG; Kropp J; Koch R; Runge R; Hliscs R
    Nuklearmedizin; 2000 Sep; 39(6):146-51. PubMed ID: 11057405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of toxicity and efficacy of 186Re-hydroxyethylidene diphosphonate in patients with painful bone metastases of prostate or breast cancer.
    Kolesnikov-Gauthier H; Carpentier P; Depreux P; Vennin P; Caty A; Sulman C
    J Nucl Med; 2000 Oct; 41(10):1689-94. PubMed ID: 11037999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short- and long-term effects of 186Re-1,1-hydroxyethylidene diphosphonate in the treatment of painful bone metastases.
    Sciuto R; Tofani A; Festa A; Giannarelli D; Pasqualoni R; Maini CL
    J Nucl Med; 2000 Apr; 41(4):647-54. PubMed ID: 10768566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose escalation study of rhenium-186 hydroxyethylidene diphosphonate in patients with metastatic prostate cancer.
    de Klerk JM; Zonnenberg BA; van het Schip AD; van Dijk A; Han SH; Quirijnen JM; Blijham GH; van Rijk PP
    Eur J Nucl Med; 1994 Oct; 21(10):1114-20. PubMed ID: 7530199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Palliative analgesic effect of Re-186 HEDP in various cancer patients with bone metastases.
    Küçük NO; Ibiş E; Aras G; Baltaci S; Ozalp G; Bedük Y; Canakci N; Soylu A
    Ann Nucl Med; 2000 Aug; 14(4):239-45. PubMed ID: 11023023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical experience with rhenium-188 HEDP therapy for metastatic bone pain].
    Róka R; Séra T; Pajor L; Thurzó L; Láng J; Csernay L; Pávics L
    Orv Hetil; 2000 May; 141(19):1019-23. PubMed ID: 10846424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiation safety considerations for the bone seeking radiopharmaceuticals. 89SrCl2, 186Re-HEDP and 153Sm-EDTMP.
    Lam MG; Hoekstra A; de Klerk JM; van Rijk PP; Zonnenberg BA
    Nuklearmedizin; 2009; 48(1):37-43. PubMed ID: 19212610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strontium-89 for palliation of pain from bone metastases in patients with prostate and breast cancer.
    Pons F; Herranz R; Garcia A; Vidal-Sicart S; Conill C; Grau JJ; Alcover J; Fuster D; Setoain J
    Eur J Nucl Med; 1997 Oct; 24(10):1210-4. PubMed ID: 9323260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 2 study of a high dose of 186Re-HEDP for bone pain palliation in patients with widespread skeletal metastases.
    Pirayesh E; Amoui M; Mirzaee HR; Tabei F; Rakhsha A; Kalantari BA; Shafiei B; Assadi M; Asli IN
    J Nucl Med Technol; 2013 Sep; 41(3):192-6. PubMed ID: 23918612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.